3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Immunoglobulin Light-chain Amyloidosis
1
Interventions
Melphalan
8
Dexamethasone
7
Bortezomib
6
Filgrastim
4
Cyclophosphamide
3
liposomal amphotericin B
2
Early Intervention, Educational
2
Darbepoetin alfa
2
Clinical Protocols
2
Calcium Dobesilate
2
ferrous sulfate
1
ferric gluconate
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
daratumumab
1
birtamimab
1
auricularum
1
Sucrose
1
Stem Cell Transplantation
1
Specimen Handling
1
Pharmacogenomic Testing
1
Peripheral Blood Stem Cell Transplantation
1
Ondansetron
1
Morphine
1
Magnetic Resonance Spectroscopy
1
Ketamine
1
Hypericum extract LI 160
1
Granulocyte Colony-Stimulating Factor
1
Fentanyl
1
Epoetin Alfa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Immunoglobulin Light-chain Amyloidosis
×
Blood Component Removal
×
Clear all
NCT02489500
2018-09-10
VelRand
Boston Medical Center
Phase 3
Terminated
3 enrolled
11 charts